Latest Conference Coverage
The magnitude of the increased risk was similar to that of having a previous cardiovascular event.
In a small study, each 1 mL/min/1.73 m2 decrease in eGFR was associated with a significant 0.020 mmol/L increase in serum sodium.
Patients discharged on Fridays and Saturday are more likely to be readmitted within 30 days than those discharged Sunday through Thursday.
The association is particularly pronounced in younger patients with higher levels of proteinuria.
Their risk of a stroke was 46% lower than that of dialysis patients.
Austrian study finds a death rate in winter of 1.60 deaths per 100 patient-months compared with 1.06 deaths per 100 patient-months in summer.
Patients discharged with home health or to a skilled nursing facility also were more likely to be readmitted.
At the end of a 22-year study period, the 1- and 3-year risk of graft loss did not differs significantly between black and white recipients.
Study reveals a 13% incidence of CIN in allograft recipients undergoing computed tomography or cardiac catheterization with contrast media.
A 30% decline in eGFR between 1 and 3 years post-transplant is associated with an increased risk of all-cause graft loss and patient death.
Study of renal transplant patients also shows that proton pump inhibitors are associated with increased arterial stiffness.
Recipients of diabetic donor kidneys—especially diabetic recipients—are at increased risk of graft loss and death.
Recipients of AKI kidneys have patient and graft survival rates similar to those of recipients of non-AKI kidneys.
Kidney recipients who lost the most weight prior to transplantation had a 25% decreased risk versus those with the most weight gain.
Recipients aged 65 years and older who receive kidneys from donors in the same age group have a higher risk of death and delayed graft function.
Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.
The protective effect was not observed with other anti-diabetic medications.
Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.
Through diet and exercise, prostate cancer patients can decrease their risk of dying from their illness.
The finding of lower bladder cancer incidence in patients receiving pelvic radiation contrasts with previous research.
Researchers estimate that 40% of pathologic response in MIBC patients receiving both neoadjuvant chemo and TURBT is due to TURBT.
A travel distance of more than 30 miles to the provider was associated with greater chances of readmission in one analysis.
Non-users of 5-alpha-reductase inhibitors had a nearly 2.6 times increased risk of pathologic progression than those who took the drugs.
Patients with higher heterogeneity score did not respond well to hormone therapy.
Second round of 6 injections was well tolerated and continued to control disease progression in bone.
A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.
Researchers observed a trend toward longer time on drug among men with castration-resistant prostate cancer.
The drug nearly doubled the delay in tumor growth compared with everolimus.
In large observational study, regular use—defined as 3 tablets per week—was associated with a 24% lower risk of dying from prostate cancer.
In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)